The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation

被引:0
作者
Annika Bergman
Zakaria Einbeigi
Ulrica Olofsson
Ziad Taib
Arne Wallgren
Per Karlsson
Jan Wahlström
Tommy Martinsson
Margareta Nordling
机构
[1] Göteborg University,Department of Clinical Genetics
[2] Sahlgrenska University Hospital,Department of Oncology
[3] Göteborg University,Department of Mathematical Statistics
[4] Sahlgrenska University Hospital,undefined
[5] Chalmers University of Technology/Göteborg University,undefined
来源
European Journal of Human Genetics | 2001年 / 9卷
关键词
BRCA1 gene; founder effect; breast neoplasm; ovarian neoplasm; haplotype;
D O I
暂无
中图分类号
学科分类号
摘要
The most recurrent BRCA1/BRCA2 mutation in Sweden is the BRCA1 mutation 3171ins5. In the western part of Sweden this mutation accounts for as much as 77% of identified mutations in these two genes. Our aim was to analyse in detail the haplotype and founder effects of the 3171ins5 and furthermore attempt to estimate the time of origin of the mutation. In the study we included eighteen apparently unrelated families with hereditary breast and/or ovarian cancer. At least one individual in each family had previously tested positive for the 3171ins5 mutation. Polymorphic microsatellite markers were used for the haplotype analyses. The markers were located within or flanking the BRCA1 gene spanning a region of 17.3 cM. We found several different haplotypes both for disease alleles and for the normal alleles. However, a conserved haplotype of 3.7 cM was observed in the 3171ins5 carriers spanning over four markers located within or very close to the BRCA1 gene. As this haplotype was not present in any of the normal controls it is highly likely that this is a mutation identical by descent, i.e. a true founder. The results from the haplotype analyses were used to estimate the age of the mutation. Estimations based on the Pexcess and linkage disequilibrium gives a first appearance of the mutation sometime around the 6th century, approximately 50 generations ago.
引用
收藏
页码:787 / 793
页数:6
相关论文
共 84 条
[1]  
Miki Y(1994)A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 266 66-71
[2]  
Swensen J(1994)Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13 Science 265 2088-2090
[3]  
Shattuck-Eidens D(1997)The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women Am J Hum Genet 60 505-514
[4]  
Wooster R(1996)Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families Nat Med 2(11) 1179-1183
[5]  
Neuhausen SL(1997)Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families Am J Hum Genet 60(5) 1059-1067
[6]  
Mangion J(1996)A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes Nat Genet 13(1) 117-119
[7]  
Abeliovich D(1994)Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families Nat Genet 8(4) 392-398
[8]  
Kaduri L(1997)A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families Am J Hum Genet 60(5) 1041-1049
[9]  
Lerer I(2000)Evidence of a founder BRCA1 mutation in Scotland Br J Cancer 82 705-711
[10]  
Tonin P(1996)New Austrian mutation in BRCA1 gene detected in three unrelated HBOC families [letter] Lancet 347 1263-1246